Skip to content
Screener

Corcept Therapeutics CORT Cash & Equivalents

Cash & Equivalents at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$121.75M+105%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$115.14M+20.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$78.64M+8.0%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$150M-39.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net effect of exchange rate changes on cash, cash equivalents and restricted cash(250)1,794
Net decrease in cash, cash equivalents and restricted cash(9,456)(24,920)
Cash, cash equivalents and restricted cash, at beginning of period121,745128,665
Cash, cash equivalents and restricted cash, at end of period$112,289$103,745
Supplemental disclosure:
Exercise cost of shares repurchased for net settlement of cashless option exercises$14,331$12,056
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents$111,039$102,745

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's cash & equivalents?
Corcept Therapeutics (CORT) reported cash & equivalents of $112.29M in Q2 2026.
How has Corcept Therapeutics's cash & equivalents changed year-over-year?
Corcept Therapeutics's cash & equivalents increased by 9.3% year-over-year, from $102.75M to $112.29M.
What is the long-term trend for Corcept Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Corcept Therapeutics's cash & equivalents has grown at a 9.8% compound annual growth rate (CAGR), from $76.19M to $121.75M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Corcept Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude